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Summary
Background The USA is currently facing a serious opioid misuse epidemic that started with increased prescribing of 
oxycodone and the inclusion of pain as a fifth vital sign, and eventually resulted in massive overdose mortality. In 
Europe, including the Netherlands, the medical use of opioids (mainly oxycodone) has also increased since 2009, but 
an increase in proxies for opioid misuse has not yet been described.
Methods For this retrospective, multi-source database study, data were requested from several national databases in 
the Netherlands to evaluate the following time trends: (1) number of people with opioid prescriptions, (2) number of 
hospital admissions related to opioid intoxication, (3) number of people treated for opioid use disorder, and (4) number 
of people who died from opioid poisoning. Data were presented as the number per 100 000 inhabitants, using 
population data over the years 2008–17 from Statistics Netherlands (Centraal Bureau voor de Statistiek). Data about 
the number of people with opioid prescriptions was obtained from the Drug Information Project (Genees- en 
hulpmiddelen Informatie Project) database hosted by the Dutch National Health Care Institute (Zorginstituut 
Nederland). Data about opioid-related hospital admissions between 2008 and 2017 were obtained from the Dutch 
National Hospital Care Basic Registration (Landelijke Basisregistratie Ziekenhuiszorg), a database managed by Dutch 
Hospital Data. Data about addiction treatment were obtained from the National Alcohol and Drugs Information 
System (Landelijk Alcohol en Drugs Informatie Systeem). Data on opioid mortality between 2008 and 2017 were 
obtained from the cause-of-death statistics database hosted by Statistics Netherlands. Each database covered almost 
the entire population of the Netherlands.
Findings Between 2008 and 2017, the overall number of prescription opioid users nearly doubled from 4109 per 
100 000 inhabitants to 7489 per 100 000 inhabitants, mainly because the number of oxycodone users quadrupled from 
574 to 2568 per 100 000 inhabitants. In the same period, the number of opioid-related hospital admissions tripled 
from 2·5 to 7·8 per 100 000 inhabitants, and between 2008 and 2015 the number of patients in addiction care for 
opioid use disorders other than heroin increased from 3·1 to 5·6 per 100 000 inhabitants. Opioid-related mortality 
was stable between 2008 and 2014 with 0·21 deaths per 100 000 inhabitants, but after 2014 it increased to 0·65 per 
100 000 inhabitants in 2017. 
Interpretation Prescription opioid use increased substantially between 2008 and 2017, and several proxies for misuse 
show a parallel increasing trend. Although the Netherlands is far from the opioid epidemic faced by the USA, safe 
opioid prescribing guidelines should be implemented to prevent further escalation and to keep opioid painkillers 
available for those in need.
Funding Radboud University Nijmegen Medical Centre.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Opioids are mostly used as analgesics in the management 
of moderate to severe pain.1–3 Effectiveness of opioids 
compared with other painkillers differs per type of pain. 
For instance, when opioids are used for the treatment 
of acute pain or chronic cancer pain most patients 
experience adequate pain reduction.3 However, there is 
little evidence for the effectiveness of opioids for chronic 
non-cancer pain.1,2 Opioids also have frequent side-effects 
such as constipation, hypoventilation, and negative effects 
on cognition and mental health.2 Effects on mental health 
particularly include hallucinations and the addictive 
potential of opioids. Approximately 3·3% of patients 
exposed to chronic opioid therapy become addicted.4 
Furthermore, opioid use is associated with an increased 
risk of suicide.5 Weighing the beneficial analgesic effects 
of opioids against their potential harms is therefore 
crucial.
The importance of balanced opioid prescription practices 
is further emphasised by the opioid epidemics in the USA 
and Canada. Between 1999 and 2010 the sales of opioids in 
the USA quadrupled,6 mainly because of increased use of 
oxycodone and the inclusion of pain as a fifth vital sign.7,8 
At the same time, opioid-related mortality increased from 
3 per 100 000 in 2000 to 7 per 100 000 in 2010.9 From 2010 
onward, the number of opioid prescriptions in the USA 
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gradually declined from roughly 80 prescriptions per 
100 people per year to about 70 per 100 people per year in 
2015.6 However, mortality caused by opioid overdose 
continued to increase to 15 per 100 000 in 2017. This is 
mainly explained by the shift from prescription opioid use 
to heroin use, and more recently to illicitly manufactured 
fentanyl.9,10 In total, an astonishing 399 233 Americans died 
from an opioid overdose between 1999 and 2017.10 Canada 
is facing a similar crisis with an overall increase in opioid-
related deaths and a stark increase in fentanyl-related 
deaths in some provinces.11
In Europe, including the Netherlands, the medical 
use of opioids has also substantially increased since 
2009.12 However, the situation in Europe may well differ 
from the USA.12 For instance, although the number of 
opioid prescriptions in Europe continues to rise, no 
increase has been described in the number of opioid-
related deaths and in the number of patients in 
addiction treatment for opioid use disorder. Between 
2007 and 2016, deaths caused by opioid overdose in 
Europe were stable at about 1·2 deaths per 100 000 per 
year,13 a much lower number than the 15 deaths per 
100 000 caused by opioid overdose in the USA in 2017.10 
Given the tremendous impact of the opioid epidemic 
sin the USA and Canada, it is of utmost importance to 
closely monitor trends in opioid use and misuse in 
Europe, in particular any signs of increased misuse of 
prescription opioids, since those could prelude large-
scale opioid-related harm and mortality. However, 
recent epidemiological studies on opioid misuse in 
Europe are scarce. The most recent evaluation12 was 
published in 2015; this narrative review used ad hoc 
data from some European countries with different data 
available for each country. Given this lack of systematic 
data, we set out to monitor trends in prescription 
opioid use and multiple proxies for opioid misuse in 
the Netherlands over the past ten years (2008–17), 
using a combination of national databases and 
registrations.
Methods
Study design
For this retrospective, multi-source database study, data 
were requested from several national databases in 
the Netherlands to evaluate the following time trends: 
(1) number of people with opioid prescriptions, (2) number 
of hospital admissions related to opioid intoxication, 
(3) number of people treated for opioid use disorder, and 
(4) number of people who died from opioid poisoning. All 
data were gathered in accordance with Dutch privacy laws 
and following the procedures required by the different 
databases. There were no exclusion criteria. As only 
aggregated data were available, individual patient data 
from the different databases could not be linked. Each 
database covered almost the entire population of the 
Netherlands. Data were presented in figures as the number 
per 100 000 inhabitants, using population data over the 
years 2008–17 from Statistics Netherlands (Centraal 
Bureau voor de Statistiek; CBS).14 Rates were calculated by 
dividing the absolute number by the number of inhabitants 
in the corresponding year and multiplying by 100 000. 
Data about the number of opioid users was obtained 
from the Drug Information Project (Genees- en hulpmi- 
ddelen Informatie Project; GIP) database hosted 
by the Dutch National Health Care Institute 
(Zorginstituut Nederland).15 This database contains 
information about reimbursements of prescriptions 
filled by public phar- macies. The data are publicly 
accessible in aggregated form and cover about 96% of all 
Dutch inhabitants. The GIP database contains 
information on the number of unique users per 
Anatomical Therapeutic Chemical (ATC) code and year. 
Research in context
Evidence before this study
The use of prescription opioids in Europe has increased 
substantially since 2009. In the USA, the rise in opioid 
prescriptions has had a major societal and medical impact, and 
has caused a marked increase in addiction and opioid-related 
deaths. It remains to be seen whether the observed increase in 
opioid prescriptions in Europe will have a similar effect. 
We searched PubMed and Google Scholar without language 
restrictions between October, 2008, and March, 2019, with the 
terms “opioid”, “use”, “misuse”, and “Europe” to identify 
relevant papers that describe recent trends in prescription opioid 
misuse in Europe. The most recent evaluation of opioid misuse 
in Europe was published in 2015, but this narrative review used 
data from only some European countries, with different data 
available for different countries. Integrated systematic 
evaluations of trends in multiple proxies for opioid misuse 
are scarce.
Added value of this study
To our knowledge, this is the first paper that uses a 
combination of national registries to explore prescription 
opioid use and several proxies for misuse, including addiction, 
hospitalisations, and mortality. Using this approach, we give an 
integrated overview of trends in use and multiple proxies for 
misuse of opioids in the Netherlands.
Implications of all the available evidence
Prescription opioid use and proxies for misuse in the Netherlands 
have increased between 2008 and 2017. Although opioid misuse 
in the Netherlands is still substantially lower than in the USA, our 
results warrant detailed monitoring of opioid misuse proxies in 
Europe. To prevent further escalation of opioid misuse and to 
keep opioid painkillers available for those in need, implementing 
safe, evidence-based opioid prescribing guidelines is of utmost 
importance.
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Currently the database covers the years 2003–17. 
Information on the duration of use or dose is unavailable 
in the publicly accessible dataset. The four most 
commonly used opioids (tramadol [ATC code N02AX02, 
N02AJ13, and N02AX52], oxycodone [N02AA05], 
morphine [N01AA01 and N02AA51], and fentanyl 
[N02AB03]) were shown separately. All other opioids 
were combined in the category of other opioids, including 
hydromorphone (N02AA03), nicomorphine (N02AA04), 
pethidine (N02AB02), dextro moramide (N02AC01), 
piritramide (N02AC03), penta zocine (N02AD01), bupre- 
norphine (N02AE01), and tapentadol (N02AX06). 
Codeine was excluded because it is not exclusively used 
for pain treatment, and the codeine plus paracetamol 
combination tablet is no longer reimbursed since 2013. 
Patients who received opioid prescriptions with different 
ATC codes were counted separately for each ATC code.
Data about opioid intoxication-related hospital 
admissions between 2008 and 2017 were obtained from 
the Dutch National Hospital Care Basic Registration 
(Landelijke Basisregistratie Ziekenhuiszorg), a database 
managed by Dutch Hospital Data.16 This database contains 
medical, administrative, and financial information on 
hospital admissions and covers all Dutch hospitals. The 
reasons for hospital admissions are coded according to the 
ninth or tenth revision of the WHO International 
Classification of Diseases (ICD-9 or ICD-10). ICD-9 was 
used until 2013 and ICD-10 was used from 2011 onward. 
Between 2011 and 2013 hospitals coded admissions using 
either ICD-9 or ICD-10. ICD-9 codes 965.00 (opium), 
965.01 (heroin), 965.02 (methadone), and 965.09 (other 
opioids), and ICD-10 codes T40.0 (opium), T40.1 (heroin), 
T40.2 (other opioids), T40.3 (methadone), and T40.4 (other 
synthetic opioids) were used to identify hospital admissions 
related to opioid poisoning. Opium (965.00 and T40.0), 
heroin (965.01 and T40.1), and methadone (965.02 and 
T40.3) were grouped into one category. All other opioids 
(965.09, T40.2 and T40.3) were combined in the category of 
other (prescription). The ICD-9 and ICD-10 codes for 
opium include preparations of opium tincture, opium 
powder, laudanum, and papaveretum. We grouped opium 
with heroin and methadone because none of the 
opium preparations are available as a prescription drug in 
the Netherlands.
Data about addiction treatment were obtained from the 
National Alcohol and Drugs Information System 
(Landelijk Alcohol en Drugs Informatie Systeem; LADIS). 
LADIS contains information about all regular addiction 
care provided in the Netherlands, to monitor changes in 
health-care consumption.17 LADIS data were available until 
2015. We extracted data on opioid-related addiction care 
between 2007 and 2015. LADIS categorises opioid-related 
addiction care into the following ten categories: heroin, 
methadone, methadone substitution, buprenorphine, 
morphine, fentanyl, oxycodone, tramadol, miscellaneous, 
and unknown opioids. We regrouped these categories, 
because of differences in registration between different 
addiction care centres. For instance, some centres register 
methadone treatment under substitution, whereas other 
centres register it as methadone. Similarly, prescription 
opioid use disorders are sometimes categorised under 
miscellaneous (this category might include patients 
receiving different prescription opioids) and sometimes 
under a specific substance like morphine or oxycodone. 
Therefore, we used three categories of patients with opioid 
use disorder in addiction care: patients with opioid use 
disorder receiving substitution treatment (including 
methadone, methadone substitution, and buprenorphine), 
patients with (prescription) opioid use disorder (including 
morphine, fentanyl, oxycodone, tramadol, and misce- 
llaneous opioids, and excluding heroin),  and patients with 
heroin use disorder. 
Data on opioid mortality between 2008 and 2017 were 
obtained from the cause-of-death statistics database 
hosted by the CBS. This database contains information 
on deaths of all Dutch inhabitants. After a death occurs, a 
physician or pathologist is required to fill out a cause-of-
death form for statistical purposes. The form is then 
Figure 1: Users of prescription opioids in the Netherlands per 
100 000 inhabitants
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Figure 2: Number of hospital admissions in the Netherlands related to opioid 
intoxication
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processed by CBS according to ICD-10 guidelines. In 
2013, CBS switched from a manual to a semi-automatic 
coding process of cause-of-death form. This limits 
comparability of data before and after 2013. Deaths 
caused by opioid poisoning are identified using ICD-10 
codes T40.0 (opium), T40.1 (heroin), T40.2 (other opioids, 
including morphine and oxycodone), T40.3 (methadone), 
and T40.4 (other synthetic opioids, including fentanyl). 
Opium (T40.0), heroin (T40.1), and methadone (T40.3) 
were grouped into a single category. Other opioids (T40.2) 
and other synthetic opioids (T40.4) were grouped as other 
(prescription) opioids. Opium was grouped with heroin 
and methadone, similar to our hospitalisation data.
Role of the funding source
The study sponsor had no role in study design, data 
collection, data analysis, data interpretation, writing of 
the report, or the decision to submit for publication. 
GAK and AS had full access to all the data in the study 
and had final responsibility for the decision to submit for 
publication.
Results
The population of the Netherlands increased from 
16·4 million in 2007 to 17·1 million in 2017. Between 2008 
and 2017, opioid use increased substantially from 4109 per 
100 000 inhabitants in 2008 to 7489 per 100 000 inhabitants 
in 2017 (figure 1). Tramadol, oxycodone, morphine, 
and fentanyl are shown separately. Hydromorphone, 
nicomorphine, pethidine, dextromoramide, piritramide, 
pentazocine, buprenorphine, and tapentadol are com- 
bined in a single category. In this 10-year period the 
number of oxycodone users almost quadrupled from 
574 to 2568 per 100 000 inhabitants. Use of fentanyl, 
morphine, and other opioids also increased, but not to 
the extent of oxycodone. The number of tramadol users 
first increased from 2736 users per 100 000 inhabitants in 
2008 to 3830 per 100 000 inhabitants in 2013 and then 
gradually declined to 3494 per 100 000 inhabitants in 2017.
Hospital admissions related to opioid intoxication 
increased from 2·5 per 100 000 inhabitants in 2008 to 
7·8 per 100 000 inhabitants in 2017. This was mainly due 
to an increase in intoxications in the category of other 
(prescription) opioids (figure 2). Intoxications involving 
opium, heroin, and methadone remained stable, 
while intoxications involving other opioids increased 
from 1·3 per 100 000 inhabitants in 2008 to 6·8 per 
100 000 inhabitants in 2017.
The total number of patients treated for opioid addiction 
decreased from 80 per 100 000 inhabitants in 2008 to 
55 per 100 000 inhabitants in 2015. More than 80% of 
opioid addiction treatments are for heroin addiction and 
the number of treatments gradually decreased from 
75 per 100 000 in 2007 to 50 per 100 000 in 2015. By 
contrast, the number of people being treated for addiction 
to other (prescription) opioids increased from 3·1 per 
100 000 inhabitants in 2007 to 5·6 per 100 000 inhabitants 
in 2015 (figure 3).
Total mortality from opioid poisoning was stable 
between 2008 and 2014 with an average of 0·21 deaths per 
100 000 (35 people). After 2014 total mortality increased to 
0·65 per 100 000 (111 people) in 2017. This increase was 
mainly driven by an increase in poisoning from other 
(prescription) opioids (figure 4). Poisoning from other 
Figure 3: Number of people in the Netherlands in addiction care
(A) Patients treated for addiction to (prescription) opioids. 
(B) Patients treated for heroin addiction, and patients receiving opioid 
substitution therapy such as methadone. 
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Figure 4: Mortality caused by opioid poisoning in the Netherlands per 
100 000 inhabitants
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(prescription) opioids was stable between 2008 and 2014 
at an average of 0·091 per 100 000 (15 people). After 2014, 
mortality from other (prescription) opioids increased to 
0·49 per 100 000 (83 people) in 2017. By contrast, mortality 
from heroin, methadone, and opium poisoning remained 
stable between 2008 and 2017 at an average of 0·13 per 
100 000 (22 people).
Discussion
Exploring trends in opioid use and proxies for opioid 
misuse in multiple databases in the Netherlands between 
2008 and 2017 showed that (1) the number of prescription 
opioid users nearly doubled, (2) the number of hospi- 
talisations caused by an opioid intoxication tripled, 
(3) addiction care for opioids other than heroin and 
substitution therapy nearly doubled, and (4) opioid-
related mortality also doubled. The relative increase in 
opioid-related hospitalisations was greater than other 
proxies for misuse, and greater than the relative increase 
in opioid prescriptions. These findings clearly show an 
increase in opioid prescriptions being paralleled by an 
increase in multiple proxies for opioid misuse. Compared 
with the USA however, the use and misuse of prescription 
opioids and opioid-related mortality are still very low.
In line with the Netherlands, other European countries 
have seen similar increases in the number of opioid 
prescriptions. For instance, in Scotland the dispensing 
of oxycodone, fentanyl, and morphine increased five-
fold between 1995 and 2010.18 Additionally, a serious 
increase in deaths caused by opioid-related overdose in 
Scotland has been observed, with 15 opioid-related 
overdose deaths per 100 000 in 2017.19 In the UK, the 
number of opioid prescriptions quadrupled between 
2000 and 2010, with most prescriptions being for non-
cancer pain.20 However, in England and Wales the 
number of deaths related to opioid overdose increased 
between 1993 and 2017, from 0·84 to 3·5 per 
100 000 inhabitants.21 Because registration of the cause 
of death in England and Wales can be delayed by months 
or even years, this number is most likely an 
underestimation. Importantly, such a delay in availability 
of monitoring data hampers adequate and timely policy 
responses. In Germany the use of strong extended-
release opioids increased four-fold between 2000 and 
2010.22 France had a doubling of strong opioid use 
between 2004 and 2017. However, it should be noted that 
the number of deaths caused by opioid overdose in the 
EU has been stable at least until 2016, at a relatively low 
rate of approximately 1·2 deaths per 100 000 inhabitants.13
Several factors might have contributed to the rise in 
prescription opioid use in the Netherlands—for example, 
an ageing population with more pain and more 
contraindications for other analgesics such as non-
steroidal anti-inflammatory drugs. However, this can 
only explain a rather small amount of the observed 
increase, since the proportion of people older than 
70 years rose from 10·3% in 2008 to 12·6% in 2017.14 
Furthermore, the increase in opioid use was seen in all 
age categories, not only in older patients.23
Since 2013, the paracetamol-codeine combination tablet 
is no longer reimbursed in the Netherlands. This might 
also have contributed to the rise of other opioids, 
particularly because the number of users of this 
combination has been fairly high in the past, with around 
2500 users per 100 000 per year before 2013. Another 
important factor might be the increased attention to pain 
treatment in Dutch hospitals. In 2009 a national hospital 
patient safety programme was started, aiming to recognise 
and treat pain early.24 This programme called for frequent 
measurement of pain scores and (mainly pharmaco-
logical) treatment of moderate to severe pain (numeric 
pain rating scale ≥4). Additionally, the percentage of 
patients with low pain scores (numeric pain rating 
scale <6) was used as an important quality indicator in the 
benchmarking between hospitals. The increased focus on 
pain management combined with increasingly short 
hospital stays has likely resulted in more patients being 
discharged with opioid prescriptions.24
Key drivers of the opioid epidemic in the USA were the 
false beliefs that opioids are safe when used for chronic 
non-cancer pain and that development of addiction is rare; 
the large-scale public advertisement of opioid painkillers, 
increasing the pressure on doctors to prescribe them; and 
the existence of opioid pharmacies (so-called pill mills).25–27 
US marketing of oxycodone by the pharmaceutical 
company Purdue is thought to have contributed 
substantially to the opioid epidemic,28 leading to trials and 
convictions of representatives of this firm. However, in 
the Netherlands public marketing by pharmaceutical 
companies is not allowed and so-called pill mills do not 
exist. Together with the warning example of the enormous 
opioid epidemic in the USA, which emphasises the 
addictive potential of prescription opioids, these factors 
might so far have prevented a similar opioid epidemic 
from happening in the Netherlands and Europe.12
Still, the number of addiction treatments for opioids 
other than heroin and methadone in the Netherlands 
nearly doubled from 2008 to 2015, paralleling the increase 
in prescription opioid users. A similar trend was observed 
in the USA, where an increase in opioid addiction 
treatments from 1999 to 2008 paralleled an increase in 
opioid sales.29 The number of opioid-related hospitalisations 
and mortality in the Netherlands increased from 2014 
onward, mainly driven by other (prescription) opioids. 
Although not an a priori hypothesis, there seems to be a 
delay between the rise in opioid prescriptions and opioid-
related mortality, in contrast with the USA where these 
developments occurred simultaneously.
The observed trends in opioid painkiller prescribing 
and proxies for misuse in the Netherlands warrant 
implementation of safe opioid prescribing guidelines to 
prevent further escalation of a potential threat to public 
health. For instance, doctors should prescribe the 
smallest quantity of opioids required to sufficiently treat 
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acute pain and only for a limited period, because chronic 
use often begins with treatment of acute pain. 
Furthermore, chronic opioid therapy should only be 
initiated when realistic goals for pain management, 
functioning, and quality of life have been established. 
Opioid therapy should be discontinued when these goals 
are not met or when the harms outweigh the benefits. 
Moreover, non-pharma- cological and non-opioid pain 
therapy should always be considered in addition to or 
instead of opioid therapy.2 To tackle the rise in opioid use, 
close collaboration between hospital prescribers (eg, 
surgeons and anaesthesiologists), addiction specialists, 
psychiatrists, general practitioners, and pharmacists is 
needed. Additionally, prescribers should take risk factors 
for opioid misuse into account when first prescribing 
opioids, so patients at risk can be monitored and guided 
more closely.30 Guidelines with respect to duration of 
opioid prescriptions should be readily available and 
implemented, and general practitioners should not 
renew prescriptions for patients on opioids without 
careful consideration. Early iden- tification of patients 
who increase or extend their opioid prescriptions is 
especially important, so that they can be referred for 
consultation with addiction specialists or psychiatrists in 
individual cases. The Dutch Ministry of Health has 
recently declared that the increase in opioid use in the 
Netherlands is a public health priority and is exploring 
how to reverse the observed trends. The increase in 
opioid use has been subject to media attention, leading 
to more vigilance on opioid misuse among prescribers 
and patients alike. Additionally, the general practitioners 
guideline for management of chronic non-cancer pain 
has been adapted and has become more conservative 
concerning indications for prescription of opioids.
A major strength of our study is the use of national 
databases that cover almost the entire population of the 
Netherlands, and the use of several proxies for misuse. 
However, we should also consider several limitations. 
First, our prescription data provide no information on 
the duration, dose, prescriber and reason for opioid 
use. Such information is of great value for more 
detailed analyses of observed trends. Moreover, such 
information would allow us to calculate morphine 
equivalents, facilitating more precise monitoring of 
opioid use. Similarly, information on specific opioids 
involved in opioid-related mortality and demand for 
addiction treatment could show which opioids might be 
most harmful. However, most countries and the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) do not differentiate between 
different prescription opioids (eg, oxycodone and 
fentanyl) and classical opioids (eg, heroin) in their data 
monitoring systems. This is highly relevant, as our data 
show that the total treatment demand for opioids in the 
Netherlands decreased over the past years (in line with 
EMCDDA data), masking an increase in treatment 
demand for prescription opioids. Although we were 
able to separate trends in heroin and heroin substitution 
therapy (methadone) from trends in prescription 
opioids, we were not able to identify which prescription 
opioids were involved in mortality and demand for 
addiction treatment  (figures 2–4). Moreover, since 
methadone is also used for treatment of pain, our 
inability to distinguish prescription opioids might have 
led to an underestimation of opioid misuse indicators.
Second, codeine was excluded because reliable data on 
codeine use for pain was not available. Codeine can be 
used in high doses as an analgesic or in lower doses as a 
cough suppressant. The GIP database does not distinguish 
between these two uses for codeine-only formulations. 
A possible option to examine codeine use for pain would 
be to only examine combination formulations that 
are exclusively used for pain. However, this would 
underestimate codeine use for pain since codeine-only 
formulations are not taken into account. Furthermore, the 
paracetamol-codeine combination tablet is no longer 
reimbursed in the Netherlands since 2013, so its use for 
pain is unlikely to have increased. Thus, the impact of the 
exclusion of codeine from our study is likely to be low, 
because use of codeine combination tablets for pain was 
stable before 2013, and the Dutch general practitioners 
guideline for management of chronic non-cancer pain 
recommends the use of tramadol instead of codeine when 
pain is insufficiently treated with paracetamol or non-
steroidal anti-inflammatory drugs. The increase in proxies 
for misuse is unlikely to be caused by misuse of 
prescription codeine; a detailed study of patient-level 
prescription data, including dose and indication, would be 
required to obtain complete information on codeine use, 
to investigate the effect of the change in reimbursement 
status.
Third, our data from addiction care do not contain 
information about the start of the opioid addiction. 
Therefore, we cannot say for certain that the increase in 
addiction to other opioids started with a prescription to a 
medical opioid. Our ability to see trends in addiction care 
is also limited to data before 2015. Additionally, treatment 
of opioid addictions in the Netherlands is mainly focused 
on illicit opioids such as heroin, so patients experiencing 
a problem with prescription opioids might seek treatment 
outside of regular addiction care—for instance at a 
general practitioner or in hospitals. This could result in 
an underestimation of the prevalence of opioid addiction 
in our data. Fourth, in recent years post-mortem 
toxicological screening has become more common, 
which could be causing an increase in opioid-related 
deaths being registered in the cause-of-death statistics 
database.31 Fifth, although our findings are in line with 
previous studies32–34 showing a clear link between the 
number of opioid prescriptions and opioid-related 
complications, the independence of datasets and 
observational nature of the data does not allow us to infer 
any causal relationships. Sixth, in the prescription data 
the number of users is provided per ATC code. This 
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means that people receiving more than one opioid might 
count double in the datasets, leading to an overestimation 
of the number of opioid users, but this does not affect the 
indices of misuse. Finally, we have no data on the way in 
which prescription opioids are misused. This is relevant 
from a public health perspective, since people who inject 
drugs are at greater risk of infection with blood-borne 
diseases. New infections with HIV and hepatitis B or C 
are currently very rare among people who inject drugs in 
the Netherlands.31 To consolidate this low number of new 
blood-borne infections, preventing further expansion of 
opioid misuse and transition to intravenous use is key. 
Taken together, our findings show that numbers of 
prescription opioid users and of several proxies for opioid 
misuse have increased in the Netherlands, but they have 
not reached the epidemic levels faced by the USA. Our 
findings stress the relevance of close monitoring and 
development of evidence-based guidelines. A similar 
retrospective, multi-source database approach can also 
shed light on opioid use and misuse in other European 
countries.
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